Advanced Therapeutics最新文献_第2页

Nanotechnology-Based Systems for Enhancing the Efficacy of Sonodynamic Therapy in Cancer Treatment

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-11-05 DOI: 10.1002/adtp.202400309

Yidong Wang, Nikolitsa Nomikou

引用次数: 0

Applications and Developments of Gene Therapy Drug Delivery Systems for Neurological Disorders

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-11-02 DOI: 10.1002/adtp.202400269

Ngoc Hong Nguyen, Phuong-Trang Nguyen-Thi, Thuy Trang Nguyen, Vu Khac Hoang Bui, Nhat Thang Thi Nguyen, Giau Van Vo

{"title":"Applications and Developments of Gene Therapy Drug Delivery Systems for Neurological Disorders","authors":"Ngoc Hong Nguyen, Phuong-Trang Nguyen-Thi, Thuy Trang Nguyen, Vu Khac Hoang Bui, Nhat Thang Thi Nguyen, Giau Van Vo","doi":"10.1002/adtp.202400269","DOIUrl":"https://doi.org/10.1002/adtp.202400269","url":null,"abstract":"Neurological diseases (NDs) such as Alzheimer's disease, Parkinson's disease, ischemic strokes, spinal cord injuries, and other similar conditions that continue to pose a substantial health and economic burden on a global scale. It is crucial to tackle the difficulties provided by current medications due to the adverse effects and its immunological reactions to develop improved treatments for neurodegenerative illnesses. Gene therapy is currently being extensively used in preclinical and clinical studies for various diseases because of its ability to enhance the delivery and effectiveness of treatments. Various gene delivery techniques, including messenger RNA, small interfering RNA, antisense oligonucleotides, microRNA, CRISPR/Cas9 system, and plasmid DNA, have been created to address these difficulties. The goal of this study is to provide a clear overview of the pathophysiological underpinnings of NDs illnesses while also illuminating recent developments in gene delivery vector technologies. It goes over the main classifications of these vectors, their individual benefits and drawbacks, and their specific applications in the delivery of gene therapy.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 12","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142868065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

DNA-Based Nanocarriers to Sequester Altered microRNAs in Cardiac Dysfunction

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-11-01 DOI: 10.1002/adtp.202400247

Alejandro Postigo, Natalia Hernández-Bellido, Marcos Sánchez-Barat, Laura García-Mendívil, Esther Pueyo, Jesús del Barrio, Silvia Hernández-Ainsa, Laura Ordovás

{"title":"DNA-Based Nanocarriers to Sequester Altered microRNAs in Cardiac Dysfunction","authors":"Alejandro Postigo, Natalia Hernández-Bellido, Marcos Sánchez-Barat, Laura García-Mendívil, Esther Pueyo, Jesús del Barrio, Silvia Hernández-Ainsa, Laura Ordovás","doi":"10.1002/adtp.202400247","DOIUrl":"https://doi.org/10.1002/adtp.202400247","url":null,"abstract":"MicroRNAs (miRs) play a critical role in modulating gene expression across biological processes, including cardiac aging and disease. As such, miRs have demonstrated therapeutic potential in several cardiac conditions. Efficient delivery of miR therapies to cardiac tissue is crucial for effective gene therapy and DNA-based nanocarriers (DNCs), based on Watson-Crick-Franklin highly specific base-pair recognition, have emerged as a promising, biocompatible alternative to viral-based methods. Here, DNCs designed to modulate miR levels as a potential treatment for cardiac dysfunction are presented. Specifically, the DNCs target miR-24-2, which inhibits SERCA2 gene. In humans, the reduction of SERCA2 activity is a hallmark of heart failure and is altered in cardiac aging. The assembled DNCs bearing anti-miR-24-2-5p sequences effectively restore intracellular levels of SERCA2 in a HEK293 cell model. The DNCs proper assembly is thoroughly verified, while their stability and miR-capture ability are demonstrated in vitro. The DNCs exhibit successful internalization into HEK293 and modest uptake into human cardiomyocytes. SERCA2 restoration by DNCs is significantly influenced by the miR-capture sequence layout, underscoring the importance of precise design for optimal biological outcomes. This study highlights the potential of DNCs in cardiac therapies, a previously unexplored avenue for addressing cardiac dysfunction.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 12","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400247","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142868082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ferric-Tannic Nanoparticles Inhibit Early-Stage Hepatocarcinogenesis by Activating Tumor Immune Responses in Rats

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-30 DOI: 10.1002/adtp.202400348

Jannarong Intakhad, Arpamas Vachiraarunwong, Rawiwan Wongpoomchai, Chalermchai Pilapong

引用次数: 0

Cocktail Polyplexes With Synchronous Flightless I siRNA and Nitric Oxide Release for Potential Chronic Wound Healing

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-23 DOI: 10.1002/adtp.202400329

Mahshid Kharaziha, Sahar Salehi, Thomas Scheibel

{"title":"Cocktail Polyplexes With Synchronous Flightless I siRNA and Nitric Oxide Release for Potential Chronic Wound Healing","authors":"Mahshid Kharaziha, Sahar Salehi, Thomas Scheibel","doi":"10.1002/adtp.202400329","DOIUrl":"https://doi.org/10.1002/adtp.202400329","url":null,"abstract":"Chronic wounds are one of the health challenges threatening human life. In these wounds, overexpression of some types of cytoskeletal actin-remodeling proteins including Flightless I (Flii) can often lead to severe skin scarring. Herein, arginine functionalized poly(β-amino ester)s are synthesized to develop polyplexes with alginate for delivery of Flii siRNA. This approach results in forming polyplexes with distinct features, such as tunable zeta potential, particle size, polydispersity, and arginine conjugation level. It is demonstrated that the uptake of arginine functionalized poly(β-amino ester)/alginate particles is composition-dependent for various cell types including J774.1 macrophages and BJ fibroblasts. Such polyplexes trigger nitric oxide release by macrophages enhancing the expression of anti-inflammatory genes while diminishing the expression of pro-inflammatory markers and demonstrating its immunomodulatory properties. Flii siRNA loaded particles provide condensed siRNA into the core-shell polyplex and exhibit controlled release of Flii siRNA over 24 h. The uptake rate of this polyplex by macrophages and fibroblasts is higher than that of a commercial gene carrier (Lipofectamine 2000), knocking down the in vitro Flii gene expression (1.3-fold). The increased BJ fibroblast proliferation and higher expression of collagen I (COL I) show the suitability of these polyplexes for wound healing.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 12","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400329","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142868945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ROS-Activatable Prodrug of Doxazolidine as Novel Cancer Therapy Paradigm

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-22 DOI: 10.1002/adtp.202400340

Ryo Tamura, Chace I. Carpenter, Charlotte M. Thomas, Ghazal Kamyabi, Hsiao-Ting Hsu, Olivia Vergnolle, Paul Balderes, Jan Grimm

{"title":"ROS-Activatable Prodrug of Doxazolidine as Novel Cancer Therapy Paradigm","authors":"Ryo Tamura, Chace I. Carpenter, Charlotte M. Thomas, Ghazal Kamyabi, Hsiao-Ting Hsu, Olivia Vergnolle, Paul Balderes, Jan Grimm","doi":"10.1002/adtp.202400340","DOIUrl":"https://doi.org/10.1002/adtp.202400340","url":null,"abstract":"Overcoming severe side effects from anticancer agents without decreasing their effects on tumor growth is a major challenge. A prodrug technology is reported using agents that are spatiotemporally activated primarily in tumors while the extratumoral toxicity to healthy cells is minimized. A ROS-activatable prodrug of a strong anticancer agent, doxazolidine (doxaz), is developed. Doxaz is a DNA alkylating agent with a half-life of 3 min and significantly higher cytotoxicity than the clinically used parental compound doxorubicin (dox). Importantly, doxaz is not affected by p-glycoprotein expression since it irreversibly alkylates DNA while dox inhibits the topoisomerase II DNA complex. As drug activators, reactive oxygen species (ROS) are already produced inside cancer cells in higher abundance than in normal cells but additionally generated by external stimuli such as radionuclides (via radiolysis of water) and/or ROS-inducing drugs. We synthesized the prodrug, Doxaz-BA, and evaluated its efficacy in vitro in cell cultures and then in vivo in xenograft mouse models. Doxaz-BA is effective in a broad range of cancer cells since most cancer cells produce higher levels of ROS. Combining with clinically relevant radiotracers such as 18F-FDG or other tumor-tropic agents / ROS inducing drugs results in a tumor-specific and enhanced localized therapy paradigm.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 12","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142868889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Overview of the Cancer Targeting Attributes of the Elastin Like Polypeptide Nano-Carriers: Discerning Active and Passive Modes

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-22 DOI: 10.1002/adtp.202400332

Ridhima Goel, Deepak Gulwani, Priyanka Upadhyay, Vijaya Sarangthem, Thoudam Debraj Singh

{"title":"An Overview of the Cancer Targeting Attributes of the Elastin Like Polypeptide Nano-Carriers: Discerning Active and Passive Modes","authors":"Ridhima Goel, Deepak Gulwani, Priyanka Upadhyay, Vijaya Sarangthem, Thoudam Debraj Singh","doi":"10.1002/adtp.202400332","DOIUrl":"https://doi.org/10.1002/adtp.202400332","url":null,"abstract":"Since the 1940s, generalized cytotoxic therapy has been a valuable tool in cancer treatment. Over the years, there's been a significant increase in developing potential cytotoxic drugs. However, little progress has been made in enhancing patients' quality of life. The therapeutic index is limited due to the drug's poor solubility and lack of selectivity. Various carriers have been explored for drug delivery to enhance efficacy. Yet, there's a gap for a versatile delivery system that can adjust to specific drug and application requirements. Here, a multifaceted drug delivery platform based on a genetically engineered nature-inspired polymer, elastin-like polypeptide (ELP) is introduced. This technology enables the customization of the polymeric vehicle's physicochemical characteristics to suit the needs of a specific drug and application. The review highlights ELP's advantages in cancer targeting, such as site-specificity, controlled release, biocompatibility, and extended plasma circulation. For the first time, ELP-based drug delivery into passive and active targeting for better comprehension of its adaptability is classified. Moreover, numerous opportunities for loading different types of drugs onto the polymer are outlined. Finally, the polymer's efficacy in delivery across multiple cancer types, underscoring the wide spectrum of ELP-based cancer drug delivery is precisely described.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 12","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142868890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Albumin-Loaded Silica Nanomaterials Functionalized with Organotin(IV) Agents: Theranostic Materials Against Triple-Negative Breast Cancer (Adv. Therap. 10/2024) 用有机锡（IV）制剂功能化的白蛋白负载二氧化硅纳米材料：针对三阴性乳腺癌的治疗材料（Adv.）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-13 DOI: 10.1002/adtp.202470021

Victoria García-Almodóvar, Karina Ovejero-Paredes, Diana Díaz-García, José M. Méndez-Arriaga, Sanjiv Prashar, Marco Filice, Santiago Gómez-Ruiz

引用次数: 0

Urine Liquid Biopsies via Highly Integrated Digital PCR System for Accurate Detection of Bladder Cancer (Adv. Therap. 10/2024) 通过高度集成的数字 PCR 系统进行尿液液体活检以准确检测膀胱癌（Adv. Therap.）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-13 DOI: 10.1002/adtp.202470020

Yue Zhang, Ming Xu, Zhihong Wu, Fan Yang, Lu Zhang, Yiquan Liu, Jiahao Lv, Shuyue Xiang, Beiyuan Fan, Zijian Zhao, Yanzhao Li, Yang Yu

引用次数: 0

Issue Information (Adv. Therap. 10/2024) 发行信息（Adv. Therap.）